blisibimod

Home
Ligands
blisibimod

Ligand id: 9518

Name: blisibimod

Summary
Biological activity
Clinical data
References
Structure
Similar ligands
Immunopharmacology

Classification
Compound class	Peptide or derivative

International Nonproprietary Names
INN number	INN
9583	blisibimod

Synonyms
Names	References
A-623
AGP3 peptibody	5
AMG 623
Fc-Agp-3	1

Database Links
Specialist databases
IMGT/mAb-DB	413
Other databases
Search PubMed clinical trials	blisibimod
Search PubMed titles	blisibimod
Search PubMed titles/abstracts	blisibimod

Comments
Blisibimod is a peptibody fusion containing four BAFF binding domains fused to a human Fc domain. By sequestering circulating BAFF ligand, it acts as a functional antagonist of BAFF interaction with the TACI receptor on B cells. Peptide sequences and structural information for this peptide are available from its IMGT/mAb-DB entry. The peptide sequence for blisibimod is claimed in Amgen's patent WO2002092620 [5].

Comments

Blisibimod is a peptibody fusion containing four BAFF binding domains fused to a human Fc domain. By sequestering circulating BAFF ligand, it acts as a functional antagonist of BAFF interaction with the TACI receptor on B cells.
Peptide sequences and structural information for this peptide are available from its IMGT/mAb-DB entry. The peptide sequence for blisibimod is claimed in Amgen's patent WO2002092620 [5].